B

BiohacksAI

Evidence-Based Biohacking

Patent Pending

23dehydrosilybin

25 PubMed studies analyzed ยท Evidence Score: 36.2

Research Domains

23dehydrosilybin has been studied across 11 research domains including ๐Ÿ”ฌ Inflammation, ๐Ÿ”ฌ Oncology, ๐Ÿ”ฅ Metabolic, ๐Ÿง˜ Stress & Anxiety, โค๏ธ Cardiovascular. The primary research focus is ๐Ÿ”ฌ Inflammation with 48% of studies addressing this area.

Loading evidence profile...

This evidence profile for 23dehydrosilybin is generated deterministically from 25 PubMed-indexed studies. All data is corpus-verified with Merkle proofs. BiohacksAI does not provide medical advice. Always consult a healthcare professional before starting any supplement regimen.

Data source: PubMed/MEDLINE (NLM). Corpus version: v20260227-01. Patent pending (EVE-PAT-2026-001). ยฉ 2026 Organiq Sweden AB.